Key facts
- It has raised $2.7M; the latest was Later Stage VC ($2.7M) in Aug 2025.
- Notable investors include Angra Partners, Polaris Investimentos.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for bioma Genetics
- ·The full record, as it builds
Funding rounds
No funding rounds for bioma Genetics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About bioma Genetics
Developer of a precision genomics platform intended to enhance cancer and reproductive health diagnostics. The company specializes in liquid biopsy, somatic panels, carrier screening, and prenatal testing, enabling clinicians and patients to make informed decisions through data-driven insights and personalized care.
- Sector
- Healthcare
- HQ
- Sao Paulo, Brazil
- Founded
- 2017
- Employees
- 32
- Website
- biomagenetics.com.br/
- Ownership
- Privately Held (backing)
bioma Genetics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in bioma Genetics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on bioma Genetics in its N-PORT filings yet. We sweep new filings monthly.